KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.

Monica Luque, Kristina Zhelyazkova, Laxmikant Vashishta, Masna Rai, Abid Sattar, Katarina Petrovic, Richard Bucknall, Steffen Leutz, Fausto Berti

BioDrugs 40(1) 135-149

PMID41182658
PMCIDPMC12790503
DOI10.1007/s40259-025-00748-8
发表日期2025-11-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:森林图/亚组分析图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。
摘要

摘要

BACKGROUND: Golimumab is a safe and effective treatment for patients with rheumatoid arthritis. Biosimilars to the reference product (RP; Simponi®) may make treatment more accessible. OBJECTIVES: The aim of this study was to assess the efficacy of AVT05, a golimumab biosimilar, and RP, each used in combination with methotrexate, in participants with moderate-to-severe rheumatoid arthritis. METHODS: This was a 52-week, randomized, double-blind, two-arm, parallel-group, active-controlled study. Participants were randomized 1:1 to receive AVT05 (n = 251) or RP (n = 251), 50 mg subcutaneously once every 4 weeks to Week 12 inclusive. Randomization was stratified by the baseline Disease Activity Score-28 for Rheumatoid Arthritis using C-Reactive Protein (DAS28-CRP) [≤ 5.1 and > 5.1]. The primary endpoint was the change from baseline in DAS28-CRP at Week 16. At Week 16, responder participants (DAS28-CRP decreased by > 0.6 from baseline and disease activity DAS28-CRP ≤ 5.1) initially enrolled in the AVT05 arm continued to receive AVT05 every 4 weeks. Responder participants initially randomized to RP were re-randomized 1:1 to either continue receiving RP or switch to AVT05. Non-responders were discontinued from the study drug. Change from baseline in DAS28-CRP response criteria at weeks 4, 8, 12, 24, 32, 40, 48, and 52 and percentage of subjects achieving American College of Rheumatology 20/50/70 at weeks 4, 8, 12, 16, 24, 32, 40, 48, and 52 were assessed as secondary endpoints. Safety and immunogenicity endpoints were also assessed. RESULTS: At Week 16, the least squares mean (standard error) change from baseline in DAS28-CRP in AVT05 and RP was - 2.89 (0.058) and - 2.98 (0.058), respectively. The two-sided 95% confidence interval of the least squares mean difference (0.09; standard error 0.082) was entirely contained within the prespecified equivalence margin of - 0.6, 0.6 (- 0.07, 0.25), supporting a demonstration of comparative efficacy. Two sensitivity analyses (one [S1] without exclusion of any data because of intercurrent events, and one [S2] excluding data following intercurrent events or relevant protocol deviations) supported the robustness of the primary endpoint estimates (S1 95% confidence interval - 0.07, 0.25; S2 95% confidence interval - 0.07, 0.25). There were no notable differences in subgroup analyses. Secondary efficacy analyses were consistent with the primary endpoint, including in participants who switched treatments. Overall safety profiles showed no clinically meaningful differences between treatments, including in participants who switched treatments. Immunogenicity profiles were comparable between treatment arms at all timepoints, including in participants who switched treatments. CONCLUSIONS: Analysis of the change in DAS28-CRP from baseline to Week 16 supported the assessment of comparative efficacy between AVT05 and RP golimumab. Secondary efficacy endpoints were consistent with this, including in participants who switched. AVT05 had a safety and immunogenicity profile similar to that observed for RP at all timepoints, including in participants who switched treatments. CLINICAL TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT05842213) and the EU Clinical Trials Register (EudraCT Number: 2022-001825-63).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Disposition of participants in the study. a Other reason for study discontinuation was a positive QuantiFERON-TB test. AE adverse event, RP reference product golimumab
非 KM Figure
Fig. 2Forest plot of 95% confidence intervals (CIs) of a change from baseline in Disease Activity Score-28 using C-Reactive Protein (DAS28-CRP) up to week 16. Two-sided 95% CIs for the difference in least squares means between AVT05 and reference product golimumab (RP) groups are obtained from a mixed-effects model for repeated measures including the treatment, visit, and treatment by visit interaction as fixed effects, and baseline DAS28-CRP as a continuous covariate. An unstructured covariance structure is used to model the within-participant error and an adjustment to the degrees of freedom is made using the Kenward Roger’s approximation. ADA anti-drug antibody, N number of participants with non-missing change from baseline in DAS28-CRP at week 16, NAb neutralizing anti-drug antibody
非 KM Figure
Fig. 3Mean (± standard deviation [SD]) change from baseline in Disease Activity Score-28 using C-Reactive Protein (DAS-28 CRP) to Week 16 by visit. Baseline is defined as the last non-missing value (scheduled, unscheduled, or repeated) before the participant received the first dose of investigational product (Day 1). Participants with an invalid DAS28-CRP at baseline ( n = 39) are excluded from this figure. RP reference product golimumab
非 KM Figure
Fig. 4Mean (± standard deviation [SD]) change from baseline in Disease Activity Score-28 using C-Reactive Protein (DAS-28 CRP) from Week 16 to end of study by visit in ‘Responder’ participants. Baseline is defined as the last non-missing value (scheduled, unscheduled, or repeated) before the participant received the first dose of investigational product (Day 1). Participants with an invalid DAS28-CRP at baseline ( n = 39) are excluded from this figure. RP reference product golimumab
非 KM Figure
Fig. 5Mean (± standard error) of serum trough pharmacokinetic concentration versus time from baseline to Week 16 (two treatment arms; panel [ a ]) and from Week 16 to Week 52 (three treatment arms; panel [ b ]). RP reference product golimumab
非 KM Figure